GSK (GSK) Stock

On Wednesday, shares of the British pharmaceutical company GSK rose significantly after it increased its long-term sales predictions and announced solid financial results for 2024. The stock jumped by 5.9% in early trading, becoming the best performer on the FTSE 100 and heading for its largest single-day increase since 2022.

GSK PLC (LSE:GSK, NYSE:GSK) saw its shares rise by 5% in early trading on Wednesday as the pharmaceutical company seemed to overcome concerns related to vaccines and reassured investors by increasing its long-term sales forecast. The company now anticipates that its revenue will surpass £40 billion by 2031, an increase from the previous estimate of £38 billion.

GSK PLC (LSE:GSK, NYSE:GSK) has increased its long-term revenue prediction, now anticipating sales to surpass £40 billion by 2031, an increase from the earlier target of £38 billion. This revision follows what the company called a "strong" financial performance in 2024, mainly due to the growth of its specialty medicines range.

GSK predicts that sales will increase by 3% to 5% in 2025 and announced fourth-quarter earnings that were better than anticipated. The strong performance in its HIV and cancer treatment areas helped balance out the decline in its vaccines sector.

NEW YORK--(BUSINESS WIRE)--Today, the well-known investor rights law firm Bernstein Litowitz Berger & Grossmann LLP (“BLB&G”) has initiated a class action lawsuit in the U.S. District Court for the Eastern District of Pennsylvania. The lawsuit claims that GSK plc (“GSK” or the “Company”) and some of its current and former executives have violated federal securities laws. This action represents all individuals or entities that bought GSK American Depositary shares.

Dublin, January 27, 2025 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has included a new report titled "Influenza Vaccines Market, Persons Vaccinated, By Segment - Vaccine Type, Indication, Technology, Route of Administration, End-user, Geography, Company Analysis - Global Forecast (2025 - 2032)."

GSK PLC has announced that it will invest £50 million in research with Oxford University to develop vaccines aimed at preventing certain types of cancer. The GSK-Oxford Cancer Immuno-Prevention Programme will explore the development of pre-cancerous cells, according to the FTSE 100 pharmaceutical company.

In 2025, the biotech and pharmaceutical industries are seeing a strong beginning for dealmaking. At the same time, a report indicates that digital health fundraising in 2024 was characterized by a "David and Goliath dynamic."

Spero Therapeutics' tebipenem, an oral carbapenem for complicated urinary tract infections (cUTIs), has a strong chance of getting approved, thanks to a successful phase 3 trial and a licensing agreement with GSK. There is a significant demand for oral carbapenems because of increasing resistance to existing oral treatments for these infections. Given its previous success in phase 3 trials and its publication in the New England Journal of Medicine, tebipenem is likely to succeed in the confirmatory phase 3 trial.